Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data in a ...

Roche has revealed the data behind a positive phase 3 trial for its oral BTK inhibitor fenebrutinib in primary progressive multiple sclerosis (PPMS), revealing that it was at least as effective as its ...

For decades, multiple sclerosis research has focused on myelin, the insulation around the brain's wiring. Scientists paid less attention to another loss that was happening in parallel: neurons in the ...

Secondary progressive MS (SPMS) typically doesn’t include complete remission like relapsing-remitting MS (RRMS), but you may experience periods when symptoms plateau or stabilize for a time.